- MustGrow study conducted by third-party lab reports 100% control of ravaging disease
- Fusarium wilt TR4 has devastated $25-billion global banana industry
- Next step in testing will evaluate patented biopesticide technology in additional lab and field settings
MustGrow Biologics (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) has released potentially industry-changing results for its initial Colombia laboratory test evaluating the effect of its proprietary mustard-derived organic biopesticide formulation on the disease Fusarium wilt TR4. MustGrow’s study, which was conducted and reported via third-party laboratory CyberAgrot SAS in Colombia using Instituto Colombiano Agropecuario (“ICA”) official protocols, reports 100% control of the disease (https://ibn.fm/XhRSH).
Sometimes called the Panama disease, Fusarium wilt TR4 has devastated the $25-billion global banana industry, reaching a point where the Colombian government actually declared a state of emergency. The lab results indicate a “unique feat — a feat MustGrow believes no other agri-science team has achieved”: controlling Fusarium wilt TR4 definitively. “This laboratory work will serve as a beachhead for more advanced testing to be used to achieve registration in Colombia and other leading banana producing countries,” MustGrow stated.
In the announcement, MustGrow outlined the CyberAgrot study results. Carefully adhering to ICA official protocols, the test evaluated samples treated with MustGrow’s natural organic biopesticide as well as control samples that were left untreated. The study tested five different rates, and all data was measured after a five-day period. In all samples, MustGrow’s biopesticide showed 100% control of Fusarium wilt TR4. By contrast, all of the control samples showed Fusarium wilt TR4 still growing.
“The CyberAgrot team is very pleased with the recent laboratory results of MustGrow’s mustard-derived product,” said industry expert and CyberAgrot general manager Alexander Chajin Robles. “This work further advances MustGrow towards our shared goal of combating the Panama disease, which has devastated the Banana Industry in Colombia and across the globe. Eliminating the disease is a national priority for the Colombian government, with the disease now affecting acres in many regions of Colombia.”
The next step in testing will evaluate MustGrow’s patented biopesticide technology in the lab to refine the dose rates and then to see levels of control of Fusarium wilt TR4 in infected field settings. Fusarium wilt TR4 is the most destructive banana disease and is particularly harmful to Cavendish bananas, which are half of all bananas produced globally Once present, the disease remains viable in soil for decades and can result in complete crop loss; currently no effective treatments exist.
“MustGrow’s product achieved 100% control of Fusarium wilt TR4, and we very much look forward to now begin field trials,” said Robles. “With further success, we will advance conversations with the Colombian Agriculture regulatory body as well as the Colombian Banana Association, accelerating MustGrow’s product as the only 100% organic solution to a growing crisis. A very exciting opportunity.”
MustGrow is an agriculture biotech company focused on providing natural, science-based biological solutions for high-value crops, including fruits and vegetables. MustGrow has designed and owns a U.S., EPA-approved natural solution that uses the mustard seed’s natural defense mechanism to protect plants from pests and diseases. More than 110 independent tests have been completed validating MustGrow’s safe and effective signature products.
The product, in granule format, is EPA-approved across many key U.S. states and by Health Canada’s Pest Management Regulatory Agency (PMRA) as a biopesticide for high-value crops such as fruit and vegetables. MustGrow has now concentrated a liquid format, called TerraMG, which, with regulatory approval, could be applied through standard drip or spray equipment, improving functionality and performance features.
For more information, visit the company’s website at www.MustGrow.ca.
NOTE TO INVESTORS: The latest news and updates relating to MGROF are available in the company’s newsroom at https://ibn.fm/MGROF
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.